+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Carrier Screening Market by Type, Medical Condition, Technology, End User, and by Region - Global Forecast to 2022-2033

  • PDF Icon

    Report

  • 200 Pages
  • January 2023
  • Region: Global
  • Quintana Research and Consulting
  • ID: 5717263
The carrier screening market size is estimated to be USD 1,525.12 million in 2022 and is expected to witness a CAGR of 12.87% during the forecast period 2023-2033 Rising local government screening programmes for inherited diseases and expanding prenatal testing in industrialized countries are some of the factors contributing to the market growth. Furthermore, rising number of newborns by assisted reproductive technology procedures such as in vitro fertilization (IVF) and various partnerships, mergers, and acquisitions, and product development by key market players are other factors supporting the market growth. However, high prices and problems with reimbursement associated with carrier testing is expected to hinder the growth.

Rising number of newborns by assisted reproductive technology procedures such as in vitro fertilization (IVF) is expected to fuel the market growth during the forecast period. Preimplantation genetic testing on embryos is a procedure used in in vitro fertilization (IVF) termed carrier screening. Before transferring embryos to the uterus, the test is carried out. This is intended to help doctors and parents choose embryos that have a minimal chance of causing genetic problems in the baby. In 2020, 73,602 babies were born in the United States as a consequence of 301,523 cycles, according to a document published by the American Society for Reproductive Medicine and released in March 2022.

Various partnerships, mergers, and acquisitions, and product development by key market players is predicted to propel the market growth during the projectced period. For instance, Oxford Nanopore Technologies announced a partnership with Bio-Techne in December 2022 to create an assay for carrier screening. In order to create a combined dry and wet lab kit for genotyping 11 key genes for carrier screening, the cooperation is anticipated to merge the long-range PCR technology of Bio-Techne and the sequencing understand of Oxford Nanopore. The objective of the initiative is to meet the growing demand from clinical labs for more accurate and comprehensive carrier screening tests.

By Type

The market is categorized into targeted disease carrier screening and expanded carrier screening. In the global market, the expanded carrier screening segment accounted for the largest revenue share in 2022 owing to the fact that ECS is a new type of carrier screening that screens for a wide range of genetic diseases irrespective of ethnicity. In order to increase their market share, the industry's players are engaging in strategic efforts such product development. For instance, in January 2022, Mitera announced the release of two genetic test products in the United States, one of which is an enhanced carrier screening test that can be done at home and helps people evaluate their risk of any of 421 genetic disorders. This improves consumer convenience and product accessibility. Similar to this, in January 2021 GeneDx, Inc. announced the release of additional genetic tests on the market, including repeat expansion analysis for Friedreich ataxia, spinocerebellar ataxia (SCA), and other prevalent types of genetic ataxias. The company's enhanced test gives customers the option to request for single- or multi-gene repeat expansion assessments. Consequently, it is anticipated that the informative test will increase the test's usage and help with personalised medical management.

By Medical Condition

The market is divided into tay-sachs, cystic fibrosis, gaucher disease, spinal muscular atrophy, sickle cell disease, and others. In 2022, the cystic fibrosis accounted for the highest revenue share due to rising knowledge about genetic disorders. For instance, Ambry Genetics launched a reproductive health programme in October 2022 that is supported by its digital platform and enhances the experience of consumers by providing genetic testing, reporting, and counselling easily accessible. Newborns are prone to more than 1,300 recessive genetic diseases. According to the American College of Obstetricians and Gynecologists, carrier screening ought to be required for all pregnant women. Cystic fibrosis (CF) is considered to be a crucial medical condition for carrier screening. When both parents carry the gene for cystic fibrosis, there is a 25% risk that the infant will also have the disease, while there is a 50% chance that the child will only be a carrier. Similar to this, Spinal Muscular Atrophy (SMA) is a prevalent recessive condition. A non-functional copy of SMN1 transmitted from parents in around 98% of affected cases.

By Technology

The market is segregated into microarrays, DNA sequencing, polymerase chain reaction, and others. In the global market, the DNA sequencing segment accounted for the largest revenue share in 2022 owing to advancements in genetic analytical techniques, including assays based on next-generation sequencing and microarray technology solutions, molecular diagnostics, and progressing the type for hereditary diseases. By September 2022, the hospital had 700 samples, up from 600 in 2020, 1,000 in 2021, and 700 in 2020. As a result, several prenatal diagnostics clinics use sequencing technology in the carrier screening tests. The market is experiencing an escalation of technological developments including chromosomal microarray and next-generation sequencing technology. The NGS-based full-exon gene sequencing is a very accurate molecular test that can identify high carriers across all racial groups, according to the National Tay-Sachs and Allied Diseases Association. For Tay-Sachs carrier screening, genotyping is expected to be less sensitive than NGS technology.

By End User

The market is segmented into physician offices & clinics, hospitals, laboratories, and others. In 2022, the hospitals segment accounted for the largest revenue share owing to the skilled professionals frequently use genetic disease testing kits in settings including hospitals and clinics. Furthermore, an increasing number of policies and insurance providers are paying for these tests, which is propelling the development of this category in the future. In 2022, the laboratory market segment held significant market share, dominating the overall market. Market participants are developing investment proposals as a result of the rising demand for genetic testing. For instance, Redcliffe Labs stated in November 2022 that it would be spending USD 10 million to increase its capacity for specialised and genetic testing. With the investment, reference laboratories will all have better NGS capabilities, faster turnaround times, and more affordable genomics. Considered to be the principal suppliers of sequencing solutions to the labs are Oxford Nanopore, Illumina, and Thermo Fisher.

Regional Markets

In 2022, North America region accounted for the highest revenue in the carrier screening market and is expected to maintain its dominance during the forecast period. This is attributed to the fact that the market participants are creating investment proposals as a result of the rising demand for genetic testing. For instance, Redcliffe Labs said in November 2022 that it will invest USD 10 million to increase its genetics and specialised testing capabilities. The investment will improve NGS abilities across all reference labs, speed up turnaround times, and create more affordable genomics. The main companies that offer sequencing solutions to labs are regarded to be Oxford Nanopore, Illumina, and Thermo Fisher. Additionally, end users are engaging in vertical mergers and acquisitions to include carrier screening services. For instance, Kindbody, a fertility and family clinic, announced in June 2022 that it had acquired Phosphorus Labs and will integrate genetic testing and screening in order to provide complete solutions. Previous to the acquisition, the clinic contracted out its preimplantation genetic testing for aneuploidy and increasing carrier screening. The rising use of carrier screening services in-house by end users is predicted to significantly affect the market's estimated value.

Competitor Insights

Some of the key players operating in the carrier screening market are Illumina, Laboratory Corporation of America Holdings, Thermo Fisher Scientific Inc., Myriad Cepheid, F. Hoffmann-La Roche Ltd, Genetics, Inc, Otogenetics, MedGenome, GeneTech, and CENTOGENE N.V.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

For instance, the availability of Mitera's at-home reproductive genetic testing products Peaches& Me and 23 Pears in all 50 states was announced in January 2022. It does test for diseases including down syndrome.

With significant support from Baillie Gifford, Neotribe Ventures, Norwest Venture Partners, Fifty Years VC, Pacific 8 Ventures, Civilization Ventures, Time BioVentures, and Libertus Capital, among others, BillionToOne raised USD 125M in Series C funding in March 2022. This round of funding was co-led by Adams Street Partners and existing investor Hummingbird Ventures.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including type, medical condition, technology, and end user from 2023 to 2033.

Segmentation: Carrier Screening Market Report 2022 - 2033

Type (Revenue, USD Million), 2022 - 2033

  • Targeted Disease Carrier Screening
  • Expanded Carrier Screening

Medical Condition (Revenue, USD Million), 2022 - 2033

  • Tay-Sachs
  • Cystic Fibrosis
  • Gaucher Disease
  • Spinal Muscular Atrophy
  • Sickle Cell Disease
  • Others

Technology (Revenue, USD Million), 2022 - 2033

  • Microarrays
  • DNA Sequencing
  • Polymerase Chain Reaction
  • Others

End User (Revenue, USD Million), 2022 - 2033

  • Physician Offices & Clinics
  • Hospitals
  • Laboratories
  • Others

By Region (Revenue, USD Million), 2022 - 2033

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM

Middle East & Africa

  • South Africa
  • GCC
  • Rest of MEA

Table of Contents

1. Research Methodology
1.1. Study Objectives
1.2. Study Scope
1.3. Research Framework
1.3.1. Research Models
1.3.1.1. Bottom-up Approach
1.3.1.2. Top-down Approach
1.3.1.3. Data Triangulation
1.3.2. Data Analysis
1.3.2.1. Data Validation
1.3.2.2. Market Size Estimation
1.3.2.3. Market Forecast Model

2. Introduction: Carrier Screening

3. Executive Summary

4. Market Dynamics
4.1. Market Drivers
4.1.1. Driver 1
4.1.2. Driver 2
4.1.3. Driver 3
4.1.4. Driver 4
4.1.5. Driver 5
4.2. Market Restraint
4.2.1. Restraint 1
4.2.2. Restraint 2
4.2.3. Restraint 3
4.2.4. Restraint 4
4.3. Market Opportunities
4.3.1. Opportunity 1
4.3.2. Opportunity 2
4.3.3. Opportunity 3
4.3.4. Opportunity 4
4.4. Market Trends
4.4.1. Trend 1
4.4.2. Trend 2
4.4.3. Trend 3
4.4.4. Trend 4
4.5. Market Challenges
4.5.1. Challenge 1
4.5.2. Challenge 2
4.5.3. Challenge 3
4.5.4. Challenge 4

5. Market Environment Analysis
5.1. Porter’s 5 Forces Analysis
5.2. PESTEL Analysis
5.3. SWOT Analysis

6. COVID-19 Impact Analysis: Carrier Screening Market

7. Market Analysis by Type
7.1. Targeted Disease Carrier Screening
7.1.1. Targeted Disease Carrier Screening Market Forecast, 2022-2033 (USD Million)
7.2. Expanded Carrier Screening
7.2.1. Expanded Carrier Screening Market Forecast, 2022-2033 (USD Million)

8. Market Analysis by Medical Condition
8.1. Tay-Sachs
8.1.1. Tay-Sachs Market Forecast, 2022-2033 (USD Million)
8.2. Cystic Fibrosis
8.2.1. Cystic Fibrosis Market Forecast, 2022-2033 (USD Million)
8.3. Gaucher Disease
8.3.1. Gaucher Disease Market Forecast, 2022-2033 (USD Million)
8.4. Spinal Muscular Atrophy
8.4.1. Spinal Muscular Atrophy Market Forecast, 2022-2033 (USD Million)
8.5. Sickle Cell Disease
8.5.1. Sickle Cell Disease Market Forecast, 2022-2033 (USD Million)
8.6. Others
8.6.1. Others Market Forecast, 2022-2033 (USD Million)

9. Market Analysis by Technology
9.1. Microarrays
9.1.1. Microarrays Market Forecast, 2022-2033 (USD Million)
9.2. DNA Sequencing
9.2.1. DNA Sequencing Market Forecast, 2022-2033 (USD Million)
9.3. Polymerase Chain Reaction
9.3.1. Polymerase Chain Reaction Market Forecast, 2022-2033 (USD Million)
9.4. Others
9.4.1. Others Market Forecast, 2022-2033 (USD Million)

10. Market Analysis by End User
10.1. Physician Offices & Clinics
10.1.1. Physician Offices & Clinics Market Forecast, 2022-2033 (USD Million)
10.2. Hospitals
10.2.1. Hospitals Market Forecast, 2022-2033 (USD Million)
10.3. Laboratories
10.3.1. Laboratories Market Forecast, 2022-2033 (USD Million)
10.4. Others
10.4.1. Others Market Forecast, 2022-2033 (USD Million)

10. Regional Market Analysis
10.2. Regional Market Trends

11. North America Carrier Screening Market
10.1. North America Carrier Screening Market
10.1.1. North America Market Size and Forecast, 2022-2033 (USD Million)
10.1.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
10.1.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
10.1.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
10.1.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
10.2. U.S. Carrier Screening Market
10.2.1. U.S. Market Size and Forecast, 2022-2033 (USD Million)
10.2.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
10.2.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
10.2.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
10.2.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
10.3. Canada Carrier Screening Market
10.3.1. Canada Market Size and Forecast, 2022-2033 (USD Million)
10.3.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
10.3.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
10.3.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
10.3.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)

11. Europe Carrier Screening Market
11.1. Europe Carrier Screening Market
11.1.1. Europe Market Size and Forecast, 2022-2033 (USD Million)
11.1.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
11.1.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
11.1.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
11.1.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
11.2. Germany Carrier Screening Market
11.2.1. Germany Market Size and Forecast, 2022-2033 (USD Million)
11.2.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
11.2.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
11.2.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
11.2.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
11.3. UK Carrier Screening Market
11.3.1. UK Market Size and Forecast, 2022-2033 (USD Million)
11.3.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
11.3.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
11.3.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
11.3.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
11.4. France Carrier Screening Market
11.4.1. France Market Size and Forecast, 2022-2033 (USD Million)
11.4.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
11.4.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
11.4.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
11.4.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
11.5. Spain Carrier Screening Market
11.5.1. Spain Market Size and Forecast, 2022-2033 (USD Million)
11.5.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
11.5.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
11.5.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
11.5.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
11.6. Italy Carrier Screening Market
11.6.1. Italy Market Size and Forecast, 2022-2033 (USD Million)
11.6.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
11.6.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
11.6.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
11.6.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
11.7. Rest of EuropeCarrier Screening Market
11.7.1. Rest of Europe Market Size and Forecast, 2022-2033 (USD Million)
11.7.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
11.7.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
11.7.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
11.7.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)

12. Asia PacificCarrier Screening Market
12.1. Asia PacificCarrier Screening Market
12.1.1. Asia Pacific Market Size and Forecast, 2022-2033 (USD Million)
12.1.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
12.1.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
12.1.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
12.1.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
12.2. Japan Carrier Screening Market
12.2.1. Japan Market Size and Forecast, 2022-2033 (USD Million)
12.2.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
12.2.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
12.2.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
12.2.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
12.3. China Carrier Screening Market
12.3.1. China Market Size and Forecast, 2022-2033 (USD Million)
12.3.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
12.3.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
12.3.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
12.3.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
12.4. India Carrier Screening Market
12.4.1. India Market Size and Forecast, 2022-2033 (USD Million)
12.4.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
12.4.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
12.4.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
12.4.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
12.5. South Korea Carrier Screening Market
12.5.1. South Korea Market Size and Forecast, 2022-2033 (USD Million)
12.5.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
12.5.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
12.5.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
12.5.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
12.6. Australia Carrier Screening Market
12.6.1. Australia Market Size and Forecast, 2022-2033 (USD Million)
12.6.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
12.6.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
12.6.1.3. Market Size and Forecast by Technology 2022-2033 (USD Million)
12.6.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
12.7. Rest of Asia Pacific Carrier Screening Market
12.7.1. Rest of Asia Pacific Market Size and Forecast, 2022-2033 (USD Million)
12.7.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
12.7.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
12.7.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
12.7.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)

13. Latin America Carrier Screening Market
13.1. Latin America Carrier Screening Market
13.1.1. Latin America Market Size and Forecast, 2022-2033 (USD Million)
13.1.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
13.1.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
13.1.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
13.1.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
13.2. BrazilCarrier Screening Market
13.2.1. Brazil Market Size and Forecast, 2022-2033 (USD Million)
13.2.1.1. Market Size and Forecast by Technology, 2022-2033 (USD Million)
13.2.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
13.2.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
13.2.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
13.3. MexicoCarrier Screening Market
13.3.1. Mexico Market Size and Forecast, 2022-2033 (USD Million)
13.3.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
13.3.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
13.3.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
13.3.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
13.4. Argentina Carrier Screening Market
13.4.1. Argentina Market Size and Forecast, 2022-2033 (USD Million)
13.4.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
13.4.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
13.4.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
13.4.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
13.5. Rest of Latin America Carrier Screening Market
13.5.1. Rest of Latin America Market Size and Forecast, 2022-2033 (USD Million)
13.5.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
13.5.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
13.5.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
13.5.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)

14. MEACarrier Screening Market
14.1. MEA Carrier Screening Market
14.1.1. MEA Market Size and Forecast, 2022-2033 (USD Million)
14.1.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
14.1.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
14.1.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
14.1.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
14.2. GCC Carrier Screening Market
14.2.1. GCC Market Size and Forecast, 2022-2033 (USD Million)
14.2.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
14.2.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
14.2.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
14.2.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
14.3. South Africa Carrier Screening Market
14.3.1. South Africa Market Size and Forecast, 2022-2033 (USD Million)
14.3.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
14.3.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
14.3.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
14.3.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)
14.4. Rest of MEA Carrier Screening Market
14.4.1. Rest of MEA Market Size and Forecast, 2022-2033 (USD Million)
14.4.1.1. Market Size and Forecast by Type, 2022-2033 (USD Million)
14.4.1.2. Market Size and Forecast by Medical Condition, 2022-2033 (USD Million)
14.4.1.3. Market Size and Forecast by Technology, 2022-2033 (USD Million)
14.4.1.4. Market Size and Forecast by End User, 2022-2033 (USD Million)

15. Competitor Analysis
15.1. Market Share Analysis, 2022
15.2. Major Recent Developments, 2019-2022

16. Company Profiles
16.1. Illumina
16.1.1. Company Snapshot
16.1.2. Company Overview
16.1.3. Financial Analysis
16.1.4. Product Benchmarking
16.1.5. Recent Developments
16.2. Laboratory Corporation of America Holdings
16.2.1. Company Snapshot
16.2.2. Company Overview
16.2.3. Financial Analysis
16.2.4. Product Benchmarking
16.2.5. Recent Developments
16.3. Thermo Fisher Scientific Inc.
16.3.1. Company Snapshot
16.3.2. Company Overview
16.3.3. Financial Analysis
16.3.4. Product Benchmarking
16.3.5. Recent Developments
16.4. Myriad Cepheid
16.4.1. Company Snapshot
16.4.2. Company Overview
16.4.3. Financial Analysis
16.4.4. Product Benchmarking
16.4.5. Recent Developments
16.5. F. Hoffmann-La Roche Ltd
16.5.1. Company Snapshot
16.5.2. Company Overview
16.5.3. Financial Analysis
16.5.4. Product Benchmarking
16.5.5. Recent Developments
16.6. Genetics, Inc
16.6.1. Company Snapshot
16.6.2. Company Overview
16.6.3. Financial Analysis
16.6.4. Product Benchmarking
16.6.5. Recent Developments
16.7. Otogenetics
16.7.1. Company Snapshot
16.7.2. Company Overview
16.7.3. Financial Analysis
16.7.4. Product Benchmarking
16.7.5. Recent Developments
16.8. MedGenome
16.8.1. Company Snapshot
16.8.2. Company Overview
16.8.3. Financial Analysis
16.8.4. Product Benchmarking
16.8.5. Recent Developments
16.9. GeneTech
16.9.1. Company Snapshot
16.9.2. Company Overview
16.9.3. Financial Analysis
16.9.4. Product Benchmarking
16.9.5. Recent Developments
16.10. CENTOGENE N. V.
16.10.1. Company Snapshot
16.10.2. Company Overview
16.10.3. Financial Analysis
16.10.4. Product Benchmarking
16.10.5. Recent Developments
16.11. Company 11
16.11.1. Company Snapshot
16.11.2. Company Overview
16.11.3. Financials
16.11.4. Medical Condition Benchmarking
16.11.5. Recent Developments
16.12. Company 12
16.12.1. Company Snapshot
16.12.2. Company Overview
16.12.3. Financials
16.12.4. Medical Condition Benchmarking
16.12.5. Recent Developments
16.13. Company 13
16.13.1. Company Snapshot
16.13.2. Company Overview
16.13.3. Financials
16.13.4. Medical Condition Benchmarking
16.13.5. Recent Developments
16.14. Company 14
16.14.1. Company Snapshot
16.14.2. Company Overview
16.14.3. Financials
16.14.4. Medical Condition Benchmarking
16.14.5. Recent Developments
16.15. Company 15
16.15.1. Company Snapshot
16.15.2. Company Overview
16.15.3. Financials
16.15.4. Medical Condition Benchmarking
16.15.5. Recent Developments
16.16. Others Prominent Players

17. Conclusion & Recommendations

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Illumina
  • Laboratory Corporation of America Holdings
  • Thermo Fisher Scientific Inc.
  • Myriad Cepheid
  • F. Hoffmann-La Roche Ltd
  • Genetics Inc
  • Otogenetics
  • MedGenome
  • GeneTech
  • CENTOGENE N.V.